NCT04334291: HOPE COVID 19

International COVID19 Clinical Evaluation Registry,

Completed Last updated 25 January 2022

What this trial tests

trial testing Observational (registry) in COVID 19 in 8,168 participants. Completed in 31 May 2020.

Timeline

23 March 2020

Primary endpoint
1 May 2020

31 May 2020

Quick facts

Lead sponsor	IVAN J NUÑEZ GIL
Status	Completed
Study type	OBSERVATIONAL
Enrollment	8,168
Start date	23 March 2020
Primary completion	1 May 2020
Estimated completion	31 May 2020
Sites	1 location across Spain

Drugs / interventions tested

• Observational (registry)

Conditions studied

• COVID 19 — all drugs for COVID 19 →

Sponsor

IVAN J NUÑEZ GIL

Who can join

Eligibility, any sex, with COVID 19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators propose to select all COVID 19 patients attended in any health center (with in hospital beds), who have been discharged or have died at the time of the evaluation.

The main objective of the present study is to carefully characterize the clinical profile of patients infected with COVID-19 in order to develop a simple prognostic clinical score allowing, in selected cases, rapid logistic decision making (discharge with follow-up, referral to provisional/field hospitals or admission to more complex hospital centers).

As secondary objectives, the analysis of the risk-adjusted influence of treatments and previous comorbidities of patients infected with the disease will be performed.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Clinical profile and predictors of in-hospital mortality among older patients hospitalised for COVID-19.
   Becerra-Muñoz VM, Núñez-Gil IJ, Eid CM, García Aguado M, et al · · 2021 · cited 76× · PMID 33201181 · DOI 10.1093/ageing/afaa258
2. Prognostic Impact of Hyponatremia and Hypernatremia in COVID-19 Pneumonia. A HOPE-COVID-19 (Health Outcome Predictive Evaluation for COVID-19) Registry Analysis.
   Ruiz-Sánchez JG, Núñez-Gil IJ, Cuesta M, Rubio MA, et al · · 2020 · cited 75× · PMID 33329400 · DOI 10.3389/fendo.2020.599255
3. Impact of renal function on admission in COVID-19 patients: an analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID 19) Registry.
   Uribarri A, Núñez-Gil IJ, Aparisi A, Becerra-Muñoz VM, et al · · 2020 · cited 73× · PMID 32602006 · DOI 10.1007/s40620-020-00790-5
4. Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry.
   Santoro F, Nuñez-Gil IJ, Vitale E, Viana-Llamas MC, et al · · 2022 · cited 48× · PMID 34611045 · DOI 10.1136/heartjnl-2021-319552
5. Clinical profile and prognosis in patients on oral anticoagulation before admission for COVID-19.
   Rivera-Caravaca JM, Núñez-Gil IJ, Vivas D, Viana-Llamas MC, et al · · 2021 · cited 43× · PMID 33080051 · DOI 10.1111/eci.13436
6. Anticoagulants for people hospitalised with COVID-19: a rapid review
   Flumignan RL, Civile VT, Tinôco JDS, Pascoal PI, et al · · 2022 · cited 41× · PMID 35244208 · DOI 10.1002/14651858.cd013739.pub2
7. Prevalence and 30-Day Mortality in Hospitalized Patients With Covid-19 and Prior Lung Diseases.
   Signes-Costa J, Núñez-Gil IJ, Soriano JB, Arroyo-Espliguero R, et al · · 2021 · cited 30× · PMID 34629634 · DOI 10.1016/j.arbres.2020.11.012
8. Non-invasive ventilation for SARS-CoV-2 acute respiratory failure: a subanalysis from the HOPE COVID-19 registry.
   Bertaina M, Nuñez-Gil IJ, Franchin L, Fernández Rozas I, et al · · 2021 · cited 30× · PMID 33727235 · DOI 10.1136/emermed-2020-210411